Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms

Clinical and Experimental Allergy

Volumn 38, Issue 6, 2008, Pages 947-956

  Roumestan, C ^a,b,d   Henriquet, C ^a,b   Gougat, C ^a,b   Michel, A ^b   Bichon, F ^b   Portet, K ^b   Jaffuel, D ^c   Mathieu, M ^a,b,e  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c Centre Médical Spécialisé de Pneumologie   (France)

^d Laboratoires Macors   (France)

^e HÔPITAL SAINT ELOI   (France)

Author keywords

5 lipoxygenase; Antagonists; Histamine H1 receptor; NF B; RANTES; Transcription factor AP 1

Indexed keywords

CIMETIDINE; DESLORATADINE; DIPHENHYDRAMINE; DOCEBENONE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOXYGENASE INHIBITOR; MIZOLASTINE; N [3 (3 PHENOXYPHENYL)ALLYL]ACETOHYDROXAMIC ACID; PHORBOL ESTER; RANTES; SYNAPSIN I; THIOPERAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG EFFECT; EPITHELIUM CELL; GENETIC TRANSFECTION; GUINEA PIG; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOFLUORESCENCE MICROSCOPY; LUNG ALVEOLUS EPITHELIUM; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REPORTER GENE; SMOOTH MUSCLE CONTRACTION; TRACHEA; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE; CHEMOKINE CCL5; EPITHELIAL CELLS; GENETIC TECHNIQUES; GUINEA PIGS; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; LIPOXYGENASE INHIBITORS; LUNG; MALE; MUSCLE, SMOOTH; NF-KAPPA B; PLASMIDS; RECEPTORS, HISTAMINE H1; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE; TRACHEA; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44249105189     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.02990.x     Document Type: Article

References (53)

1. Benavides J, Schoemaker H, Dana C et al. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittelforschung 1995 45 : 551 8.
2. Rosenzweig P, Thebault JJ, Caplain H et al. Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allergy 1992 69 : 135 9.
3. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001 107 : 751 62.
4. Vignola AM, Crampette L, Mondain M et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995 50 : 200 3.
5. Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997 27 : 1167 74.
6. Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997 27 : 559 67.
7. Carayol N, Crampette L, Mainprice B et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy 2002 57 : 1067 70.
8. Triggiani M, Giannattasio G, Balestrieri B et al. Differential modulation of mediator release from human basophils and mast cells by mizolastine. Clin Exp Allergy 2004 34 : 241 9.
9. Grundmann JU, Bockelmann R, Bonnekoh B, Gollnick HP. UV erythema reducing capacity of mizolastine compared to acetylsalicylic acid or both combined in comparison to indomethacin. Photochem Photobiol 2001 74 : 587 92.
10. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001 31 : 1369 77.
11. Mullol J, Roca-Ferrer J, Alobid I et al. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin Exp Allergy 2006 36 : 52 8.
12. Kreutner W, Hey JA, Anthes J, Barnett A, Young S, Tozzi S. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000 50 : 345 52.
13. Vargaftig BB. Mechanisms of experimental bronchopulmonary hyperresponsiveness as related to eosinophils. In : Langer SZ, Church MK, Vargaftig BB, Nicosia S, eds. New developments in the therapy of allergic disorders and asthma. Basel : International Academy for Biomedical and Drug Research, Karger, 1993 27 32.
14. Goldhill J, Pichat P, Roome N, Angel I, Arbilla S. Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzneimittelforschung 1998 48 : 179 84.
15. Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneimittelforschung 1998 48 : 173 8.
16. Brach MA, de Vos S, Arnold C, Gruss HJ, Mertelsmann R, Herrmann F. Leukotriene B4 transcriptionally activates interleukin-6 expression involving NF-kappaB and NF-IL6. Eur J Immunol 1992 22 : 2705 11.
17. Arnold R, Rihoux J, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999 29 : 1681 91.
18. Papi A, Papadopoulos NG, Stanciu LA, Degitz K, Holgate ST, Johnston SL. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001 108 : 221 8.
19. Yoneda K, Yamamoto T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997 73 : 145 53.
20. Aoki Y, Qiu D, Zhao GH, Kao PN. Leukotriene B4 mediates histamine induction of NF-kappaB and IL-8 in human bronchial epithelial cells. Am J Physiol 1998 274 : L1030 9.
21. Megson AC, Walker EM, Hill SJ. Role of protein kinase Calpha in signaling from the histamine H(1) receptor to the nucleus. Mol Pharmacol 2001 59 : 1012 21.
22. Nelson P, Kim H, Manning W, Goralski T, Krensky A. Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 1993 151 : 2601 12.
23. Donovan CE, Mark DA, He HZ et al. NF-kappa B/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J Immunol 1999 163 : 6827 33.
24. Pastore S, Giustizieri ML, Mascia F, Giannetti A, Kaushansky K, Girolomoni G. Dysregulated activation of activator protein 1 in keratinocytes of atopic dermatitis patients with enhanced expression of granulocyte/macrophage- colony stimulating factor. J Invest Dermatol 2000 115 : 1134 43.
25. Corren J. The connection between allergic rhinitis and bronchial asthma. Curr Opin Pulm Med 2007 13 : 13 8.
26. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996 154 : 1505 10.
27. de Magalhaes Simoes S, dos Santos MA, da Silva Oliveira M et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005 35 : 602 11.
28. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2001 2 : 33 46.
29. Hooker CS, Calkins PJ, Fleisch JH. On the measurement of vascular and respiratory smooth muscle responses in vitro. Blood Vessels 1977 14 : 1 11.
30. Pearson WR, Wood T, Zhang Z, Miller W. Comparison of DNA sequences with protein sequences. Genomics 1997 46 : 24 36.
31. Mathieu M, Gougat C, Jaffuel D et al. The glucocorticoid receptor gene as a candidate for gene therapy in asthma. Gene Ther 1999 6 : 245 52.
32. Roumestan C, Henriquet C, Bousquet J, Mathieu M. Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Clin Exp Allergy 2003 33 : 895 901.
33. Henriquet C, Gougat C, Combes A, Lazennec G, Mathieu M. Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells. Lung Cancer 2007 56 : 167 74.
34. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine h(1)-receptor activation of nuclear factor-kappab: roles for gbetagamma- and galpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001 60 : 1133 42.
35. Hu Q, Deshpande S, Irani K, Ziegelstein RC. [Ca(2+)](i) oscillation frequency regulates agonist-stimulated NF-kappaB transcriptional activity. J Biol Chem 1999 274 : 33995 8.
36. Kanda N, Watanabe S. Histamine enhances the production of granulocyte-macrophage colony-stimulating factor via protein kinase Calpha and extracellular signal-regulated kinase in human keratinocytes. J Invest Dermatol 2004 122 : 863 72.
37. Bakker RA, Wieland K, Timmerman H, Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur J Pharmacol 2000 387 : R5 7.
38. Anthes JC, Gilchrest H, Richard C et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol 2002 449 : 229 37.
39. Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005 5 : 8.
40. Maeda A, Matsushita K, Yamazaki F, Kawada A, Tezuka T, Aragane Y. Terfenadine antagonism against interleukin-4-modulated gene expression of T cell cytokines. J Invest Dermatol 2003 121 : 490 5.
41. Chung KF. Chemokines. In : Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, eds. Asthma. Philadelphia : Lippincott-Raven Publishers, 1997 673 82.
42. Teran LM. CCL chemokines and asthma. Immunol Today 2000 21 : 235 42.
43. Tateson JE, Randall RW, Reynolds CH et al. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol 1988 94 : 528 39.
44. Yoshimoto T, Yokoyama C, Ochi K et al. 2,3,5-Trimethyl-6-(12-hydroxy-5, 10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta 1982 713 : 470 3.
45. Chosidow O, Dubruc C, Danjou P et al. Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine. Eur J Clin Pharmacol 1996 50 : 327 33.
46. Huang SM, Chiou WL. Pharmacokinetics and tissue distribution of chlorpheniramine in rabbits after intravenous administration. J Pharmacokinet Biopharm 1981 9 : 711 23.
47. MacIntyre AC, Cutler DJ. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos 1988 9 : 513 26.
48. Chand N, Adusumalli VE, Nolan K et al. Pharmacodynamic and pharmacokinetic studies with azelastine in the guinea pig: evidence for preferential distribution into the lung. Allergy 1993 48 : 19 24.
49. Wahn U. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998 9 : 116 24.
50. Simons FE. Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma? Clin Exp Allergy 1999 29 (Suppl 3) : 98 104.
51. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002 89 : 485 91.
52. Nelson HS. Prospects for antihistamines in the treatment of asthma. J Allergy Clin Immunol 2003 112 : S96 100.
53. Baena-Cagnani CE, Berger WE, DuBuske LM et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003 130 : 307 13.